Показано 0 из 0
Дата |
---|
18:42 |
09.05.2024 |
06.05.2024 |
22.04.2024 |
02.04.2024 |
26.03.2024 |
21.03.2024 |
20.03.2024 |
18.03.2024 |
12.03.2024 |
Bid | Ask |
Open |
Min | Max |
Last |
Legal close |
Avg |
Оборот |
Кол-во сделок |
---|---|---|---|---|---|---|---|
0.035
|
0.0458
|
0.0602
|
0.035
|
0.0602
|
0.0351
|
|
|
340.27
|
70.00
|
0.035
|
0.079
|
0.0363
|
0.036
|
0.0365
|
0.036
|
|
|
105.59
|
7.00
|
0.036
|
0.079
|
0.0636
|
0.0636
|
0.07
|
0.07
|
|
|
205.88
|
11.00
|
0.036
|
0.07
|
0.0691
|
0.0691
|
0.0691
|
0.0691
|
|
|
69.10
|
1.00
|
0.03
|
0.07
|
0.033
|
0.033
|
0.0699
|
0.0699
|
|
|
107.90
|
12.00
|
0.03
|
0.07
|
0.066449
|
0.066449
|
0.066449
|
0.066449
|
|
|
35.03
|
5.00
|
0.03
|
0.07
|
0.0695
|
0.0693
|
0.0699
|
0.0698
|
|
|
42.15
|
6.00
|
0.0301
|
0.07
|
0.0482
|
0.0482
|
0.0699
|
0.0698
|
|
|
1 130.05
|
18.00
|
0.03
|
0.07
|
0.04
|
0.033
|
0.04
|
0.0352
|
|
|
508.94
|
11.00
|
0.03
|
0.07
|
0.0301
|
0.0301
|
0.0334
|
0.0334
|
|
|
32.82
|
12.00
|
Estrella Immunopharma, Inc. operates as a preclinical-stage biopharmaceutical company. The Company focuses on developing CD19 and CD22-targeted T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors. Estrella Immunopharma serves customers worldwide.